Ketamine molecule:

Image from PubChem

Ketamine Clinical Trials

Intranasal Ketamine In the Treatment of Pediatric Bipolar Disorder

To see complete record on, please visit this link

Id: NCT01504659

Organisation Name: Juvenile Bipolar Research Foundation

Overal Status: Terminated

Start Date: July 2012

Last Update: March 16, 2017

Lead Sponsor: Juvenile Bipolar Research Foundation

Brief Summary: The investigators plan to evaluate the efficacy and safety of intranasal Ketalar (ketamine hydrochloride) in the treatment of primary symptom manifestations of pediatric bipolar disorder; Fear of Harm (FOH) phenotype. This phenotype represents those children who are most resistant to traditional treatments and suffer repeated hospitalizations. Primary symptoms include fearfulness, aggression secondary to threat, mood and/or arousal instability, and psychosis. In addition to evaluation of efficacy and safety, the investigators will also analyze whether therapeutic response depends upon the degree to which the subject fits the FOH phenotype.

  • Bipolar Disorder

Total execution time in seconds: 0.29391598701477